Completed PHASE1 INTERVENTIONAL 2-arm NCT00496509

Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer

A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients With Advanced Colorectal Cancer and Liver Metastases

Sponsor: Genzyme, a Sanofi Company

Conditions Colorectal Cancer

Interventions Biomarker Draws Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR) ZD6474 (Zactima) 100mg ZD6474 (Zactima) 300mg

Updated 5 times since 2017 Last updated: Aug 25, 2016 Started: Aug 31, 2006 Primary completion: Oct 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Colorectal Cancer and is currently completed. Genzyme, a Sanofi Company leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genzyme, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Freiberg, Germany